Dr. Zhou Lihan

Dr. Zhou Lihan is the Co-founder and CEO of MiRXES. Dr. Zhou oversees MiRXES’s overall strategy and global operations, and has propelled the company into a leader in disease early detection. Prior to founding MiRXES, Dr. Zhou led a research team at the Bioprocessing Technology Institute, A*STAR to develop a novel microRNA (miRNA) qPCR assay platform for biomarker and therapeutic target discovery. In 2015, Dr. Zhou was recognized by MIT Technology Review as a member of “Innovators Under 35”. Dr. Zhou obtained his PhD, Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. He has authored and co-authored more than 20 peer-reviewed publications and has several patent applications.

About MiRXES 

MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests.

MiRXES’ story began in early 2000 when the founders pioneered a highly sensitive, specific and robust detection technology for MicroRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic and infectious diseases, MiRXES decided to bring its technology from laboratory to clinic. In 2014, MiRXES spun off from A*STAR to commercialize the technology, develop accurate multi-cancer early detection solutions and make them readily available and accessible.

MiRXES believes that the future of health care will shift from treating the sick to preventive health care. The company’s focus on science and innovation will continue as it commits to changing lives and delivering preventive health care solutions to all.

Website: mirxes.com